Selected studies in pediatric aggressive B-cell lymphomas
| Trial . | No. . | Histology . | Age, y . | Stage . | Regimen . | EFS . |
|---|---|---|---|---|---|---|
| Woessmann33 (BFM-95) | 505 | BL/DLBCL | Median 9.3 | All stages | BFM95 | 89% @ 3 y |
| Gerrard34 (FAB/LMB96) | 132 | BL/DLBCL | Median 10 | I-II | COPAD | 98.3% @ 4 y |
| Minard-Colin36 (Inter-B-NHL) | 310 | BL/DLBCL (and B-ALL) | All <18 | III-IV | LMB-96 + R | 94.2% @ 1 y |
| LMB-96 | 81.5% @ 1 y | |||||
| Gerrard51 (FAB/LMB96) | 42 | PMBCL | Median 16 | III | FAB LMB 96 | 66% @ 5 y |
| Trial . | No. . | Histology . | Age, y . | Stage . | Regimen . | EFS . |
|---|---|---|---|---|---|---|
| Woessmann33 (BFM-95) | 505 | BL/DLBCL | Median 9.3 | All stages | BFM95 | 89% @ 3 y |
| Gerrard34 (FAB/LMB96) | 132 | BL/DLBCL | Median 10 | I-II | COPAD | 98.3% @ 4 y |
| Minard-Colin36 (Inter-B-NHL) | 310 | BL/DLBCL (and B-ALL) | All <18 | III-IV | LMB-96 + R | 94.2% @ 1 y |
| LMB-96 | 81.5% @ 1 y | |||||
| Gerrard51 (FAB/LMB96) | 42 | PMBCL | Median 16 | III | FAB LMB 96 | 66% @ 5 y |
B-ALL, B-cell acute lymphoblastic leukemia; EFS, event-free survival.